Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492318 | 0.83 | LMNA (0.39) | LMNAADH1BADH1CADH1AMGLL | |
| SCHEMBL5933090 | 0.81 | LMNA (0.45) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL14214894 | 0.79 | LMNA (0.46) | LMNAADH1BADH1CADH1ATSHR | |
| SCHEMBL6950289 | 0.77 | TSHR (0.45) | LMNAADH1BADH1CADH1APPARG | |
| SCHEMBL2141079 | 0.77 | — | — | |
| SCHEMBL12083573 | 0.76 | FAAH (0.49) | ADH1BADH1CADH1AMGLLDAGLA | |
| SCHEMBL13847399 | 0.76 | FAAH (0.49) | ADH1BADH1CADH1AMGLLDAGLA | |
| SCHEMBL8852297 | 0.76 | LMNA (0.45) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL12085801 | 0.75 | ALDH1A1 (0.38) | LMNAADH1BADH1CADH1ATSHR | |
| SCHEMBL12083492 | 0.75 | ALDH1A1 (0.38) | LMNAADH1BADH1CADH1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258321-B2 | Beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258321-B2 | Beta-lactone compounds | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009059046-A1 | BETA-LACTONE COMPOUNDS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-07 | — | — | WO | disclosed |
| US-7129256-B2 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-0933379-B1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20030191120-A1 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1321151-A1 | ANTIPARKINSONISM DRUGS | SHIONOGI & CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| EP-0936218-B1 | BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-0436902-B1 | 5-Fluorouracil derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0647632-A1 | NOVEL BENZODIAZEPINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124681-A1 | BETA-LACTONE COMPOUNDS | LBR, CYP8B1, GLB1 | LMNA 469/4885ADH1B 271/4885ADH1C 180/4885 |
| US-20030191120-A1 | Antiparkinsonism drugs | PARK7, SNCA, NLN | LMNA 1509/4885ADH1B 2085/4885ADH1C 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.